STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be an effective
treatment for leukemia.
PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have
chronic myelogenous leukemia in blast crisis.